t e c h n i c a l r e p o r t s Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient coverage for broad clinical applicability. Here we introduce cancer personalized profiling by deep sequencing (CAPP-Seq), an economical and ultrasensitive method for quantifying ctDNA. We implemented CAPP-Seq for non-small-cell lung cancer (NSCLC) with a design covering multiple classes of somatic alterations that identified mutations in >95% of tumors. We detected ctDNA in 100% of patients with stage II-IV NSCLC and in 50% of patients with stage I, with 96% specificity for mutant allele fractions down to ~0.02%. Levels of ctDNA were highly correlated with tumor volume and distinguished between residual disease and treatment-related imaging changes, and measurement of ctDNA levels allowed for earlier response assessment than radiographic approaches. Finally, we evaluated biopsy-free tumor screening and genotyping with CAPP-Seq. We envision that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy.
Analysis of ctDNA has the potential to revolutionize detection and monitoring of tumors. Noninvasive access to cancer-derived DNA is particularly attractive for solid tumors, which cannot be repeatedly sampled without invasive procedures. In NSCLC, PCR-based assays have been used to detect recurrent point mutations in genes such as KRAS (encoding kirsten rat sarcoma viral oncogene homolog) or EGFR (encoding epidermal growth factor receptor) in plasma DNA [1] [2] [3] [4] , but the majority of patients lack mutations in these genes. Recently, approaches employing massively parallel sequencing have been used to detect ctDNA [5] [6] [7] [8] [9] [10] [11] [12] . However, the methods reported to date have been limited by modest sensitivity 13 , applicability to only a minority of patients, the need for patient-specific optimization and/or cost. To overcome these limitations, we developed a new strategy for analysis of ctDNA. Our approach, called CAPP-Seq, combines optimized library preparation methods for low DNA input masses with a multiphase bioinformatics approach to design a 'selector' consisting of biotinylated DNA oligonucleotides that target recurrently mutated regions in the cancer of interest. To monitor ctDNA, the selector is applied to tumor DNA to identify a patient's cancer-specific genetic aberrations and then directly to circulating DNA to quantify them ( Fig. 1a) . Here we demonstrate the technical performance and explore the clinical utility of CAPP-Seq in patients with early-and advancedstage NSCLC.
RESULTS

Design of a CAPP-Seq selector for NSCLC
For the initial implementation of CAPP-Seq, we focused on NSCLC, although our approach is generalizable to any cancer for which recurrent mutations have been identified. To design a selector for NSCLC ( Fig. 1b, Supplementary Table 1 and Online Methods), we began by including exons covering recurrent mutations in potential driver genes from the Catalogue of Somatic Mutations in Cancer (COSMIC) 14 and other sources 15, 16 . Next, using whole-exome sequencing (WES) data from 407 patients with NSCLC profiled by The Cancer Genome Atlas (TCGA), we applied an iterative algorithm to maximize the number of missense mutations per patient while minimizing selector size ( Supplementary Fig. 1 and Supplementary Table 1 ).
Approximately 8% of NSCLCs harbor rearrangements involving the receptor tyrosine kinase genes ALK (encoding anaplastic lymphoma receptor tyrosine kinase), ROS1 (encoding c-ros oncogene 1 tyrosine kinase) or RET proto-oncogene [17] [18] [19] [20] [21] . To utilize the low false detection rate inherent in the unique junctional sequences of structural rearrangements 5,6 , we included the introns and exons spanning recurrent fusion breakpoints in these genes in the final design phase ( Fig. 1b) . To detect fusions in tumor and plasma DNA, we developed a breakpoint-mapping algorithm optimized for ultradeep coverage data (Supplementary Methods). Application of this algorithm to next-generation sequencing (NGS) data from two NSCLC cell lines known to harbor fusions with previously uncharacterized breakpoints 22, 23 readily identified the breakpoints at nucleotide resolution ( Supplementary Fig. 2) .
Collectively, the NSCLC selector design targets 521 exons and 13 introns from 139 recurrently mutated genes, in total covering ~125 kb ( Fig. 1b) . Within this small target (0.004% of the human genome), the selector identifies a median of four single nucleotide variants (SNVs) and covers 96% of patients with lung adenocarcinoma or squamous cell carcinoma. To validate the number of mutations covered per tumor, we examined the selector region in WES data from an independent cohort of 183 patients with lung adenocarcinoma 20 . The selector covered 88% of patients with a median of four SNVs per patient, approximately fourfold more than would be expected from random sampling of the exome (P < 1.0 × 10 −6 ; Fig. 1c ), thus validating our selector design algorithm.
Methodological optimization and performance assessment
We performed deep sequencing with the NSCLC selector to achieve ~10,000× coverage (preduplication removal) based on considerations of sequencing depth, median number of reporters and ctDNA detection limit ( Fig. 1d) . We profiled a total of 90 samples, including two NSCLC cell lines, 17 primary tumor samples with matched peripheral blood leukocytes (PBLs) and 40 plasma samples from 18 human subjects, including 5 healthy adults and 13 patients with NSCLC ( Supplementary  Table 2 ). To assess and optimize selector performance, we first applied it to circulating DNA purified from healthy control plasma and observed efficient and uniform capture of genomic DNA ( Supplementary Table 2 ). Sequenced plasma DNA fragments had a median length of ~170 bp ( Fig. 2a) , which closely corresponds to the length of DNA contained within a chromatosome 24 . By optimizing library preparation from small quantities of plasma DNA, we increased recovery efficiency by >300% and decreased bias for libraries constructed from as little as 4 ng of DNA ( Supplementary Fig. 3 ). Consequently, fluctuations in sequencing depth were minimal (Fig. 2b,c) .
The detection limit and accuracy of CAPP-Seq are affected by (i) the input number and recovery rate of circulating DNA molecules, (ii) sample cross-contamination, (iii) potential allelic bias in the capture reagent and (iv) PCR or sequencing errors. We examined each of these elements in turn. First, by comparing the number of input DNA molecules per sample with estimates of library complexity ( Supplementary Fig. 4a and Supplementary Methods), we calculated a circulating DNA molecule recovery rate of ≥49% ( Supplementary  Table 2 ). This was in agreement with molecule recovery yields calculated following PCR (Supplementary Fig. 4b ). Second, by analyzing patient-specific homozygous single nucleotide polymorphisms (SNPs) across samples, we found cross-contamination of ~0.06% in multiplexed plasma DNA ( Supplementary Fig. 4c and Supplementary Methods), prompting us to exclude any tumor-derived SNV from further analysis if found as a germline SNP in another profiled patient. Next, we evaluated the allelic skew in heterozygous germline SNPs within patient PBL samples and observed minimal bias toward capture of reference alleles (Supplementary Fig. 4d ). Finally, we analyzed the distribution of nonreference alleles across the selector for the 40 plasma DNA samples, excluding tumor-derived SNVs and germline SNPs. We found mean and median background rates of 0.006% and 0.0003%, respectively ( Fig. 2d) , both considerably lower than previously reported NGS-based methods for ctDNA analysis 8, 10 .
Nongermline plasma DNA could be present in the absence of cancer owing to contributions from preneoplastic cells from diverse npg t e c h n i c a l r e p o r t s tissues, and such 'biological' background may also affect CAPP-Seq sensitivity. We hypothesized that biological background, if present, would be particularly high for recurrently mutated positions in known cancer driver genes and therefore analyzed mutation rates of 107 cancer-associated SNVs 25 in all 40 plasma samples, excluding somatic mutations found in each patient's tumor. Although the median fractional abundance was comparable to the global selector background (~0%), the mean was marginally higher at ~0.01% ( Fig. 2e) . Notably, we detected one mutational hotspot (tumor suppressor TP53, R175H) at a median frequency of ~0.18% across all plasma DNA samples, including those from patients and healthy subjects ( Fig. 2f) . As we observed the frequency of this TP53 mutant allele to be significantly above global background (P < 0.01), we hypothesize that it reflects true biological clonal heterogeneity and thus excluded it as a potential reporter. To address background more generally, we also normalized for allele-specific differences in background rate when assessing the significance of ctDNA detection (Supplementary Methods). As a result, we found that biological background is not a major factor affecting ctDNA quantitation at detection limits above ~0.01%. Next, we empirically benchmarked the detection limit and linearity of CAPP-Seq ( Fig. 2g and Supplementary Fig. 5a ). We accurately detected defined inputs of NSCLC DNA at fractional abundances between 0.025% and 10% with high linearity (R 2 ≥ 0.994). We observed only marginal improvements in error metrics above a threshold of four SNP reporters (Fig. 2h,i and Supplementary Fig. 5b,c) , which is equivalent to the median number of SNVs per tumor identified by the selector. Moreover, the fractional abundance of fusion breakpoints, npg insertions and deletions (indels) and copy number alterations (CNAs) correlated highly with expected concentrations (R 2 ≥ 0.97; Supplementary Fig. 5d ).
Somatic mutation detection and tumor burden quantitation
We next applied CAPP-Seq to the discovery of somatic mutations in tumor samples collected from 17 patients with NSCLC ( Table 1 and Supplementary Table 3 ), including formalin-fixed surgical resections, needle biopsy specimens and malignant pleural fluid. At a mean sequencing depth of ~5,000× (preduplicate removal) in tumor and paired germline samples ( Supplementary Table 2 ), we detected 100% of previously identified SNVs and fusions and discovered many additional somatic variants ( Table 1 and Supplementary Table 3 ). Moreover, we characterized breakpoints at base-pair resolution and identified partner genes for each of eight known fusions involving ALK or ROS1 (Supplementary Fig. 2 ). Tumors containing fusions were almost exclusively from never-smokers and contained fewer SNVs than those lacking fusions, as expected 21 (Supplementary Fig. 2 ).
Excluding patients with fusions, we identified a median of six SNVs (three missense) per patient ( Table 1) , in line with our selector designstage predictions (Fig. 1b,c) .
Next, we assessed the sensitivity and specificity of CAPP-Seq for disease monitoring and minimal residual disease detection using plasma samples from 5 healthy controls and 35 samples collected from 13 patients with NSCLC ( Table 1 and Supplementary Table 4 ). We integrated information content across multiple instances and classes of somatic mutations into a ctDNA detection index. This index is analogous to a false-positive rate and is based on a decision tree in which fusion breakpoints take precedence because of their nonexistent background and in which P values from multiple reporter types are integrated (Online Methods). When we applied this approach in a receiver operating characteristic (ROC) analysis, CAPP-Seq achieved an area under the curve (AUC) of 0.95, with maximal sensitivity and specificity of 85% and 96%, respectively, for all plasma DNA samples from untreated patients and healthy controls. Sensitivity among patients with stage I tumors was 50%, and among those with stage II-IV tumors, it was 100%, with a specificity for both groups of 96% ( Fig. 3a,b) . Moreover, when considering both pre-and post-treatment samples, CAPP-Seq exhibited robust performance, with AUC values of 0.89 for all stages and 0.91 for stages II-IV (P < 0.0001, Z-test, Online Methods; Supplementary Fig. 6 ). Furthermore, by adjusting the ctDNA detection index, we could increase specificity up to 98% Fig. 6 ). Thus, CAPP-Seq can achieve robust assessment of tumor burden and can be tuned to deliver a desired sensitivity and specificity.
Monitoring of NSCLC tumor burden in plasma samples
We next asked whether significantly detectable levels of ctDNA correlate with radiographically measured tumor volumes and clinical responses to therapy. Fractions of ctDNA detected in plasma by SNV and/or indel reporters ranged from ~0.02% to 3.2% ( Table 1) , with a median of ~0.1% in pretreatment samples. Absolute levels of ctDNA in pretreatment plasma significantly correlated with tumor volume as measured by computed tomography (CT) and positron emission tomography (PET) imaging (R 2 = 0.89, P = 0.0002; Fig. 3c ).
To determine whether ctDNA concentrations reflect disease burden in longitudinal samples, we analyzed plasma DNA from three patients with advanced NSCLC undergoing distinct therapies (Fig. 4a-c) . As in pretreatment samples, ctDNA levels highly correlated with tumor volumes during therapy (R 2 = 0.95 for patient 15 (P15); R 2 = 0.85 for P9). This behavior was observed whether the mutation types measured were a collection of SNVs and an indel (P15, Fig. 4a ), multiple fusions (P9, Fig. 4b ) or SNVs and a fusion (P6, Fig. 4c ). Of note, in Table 1 were examined for the presence of mutant allele outliers without knowledge of the primary tumor mutations ( Supplementary Methods) ; samples with detectable mutations are shown, along with three samples assumed to be cancer-negative (P1-2, P1-3 and P16-3; Supplementary Methods) . The number following the hyphen in each sample (e.g., -1) represents the plasma time point (Supplementary Table 4 ). The lowest fraction of ctDNA among positive samples was ~0.4% (dashed horizontal line). Data in d are expressed as mean ± s.e.m. Scale bars (a,b,e-h), 10 cm.
npg one patient (P9), we identified both a classic EML4-ALK fusion and two previously unreported fusions involving ROS1: FYN-ROS1 and ROS1-MKX (Supplementary Fig. 2) . All fusions were confirmed by quantitative PCR (qPCR) amplification of genomic DNA and were independently recovered in plasma samples ( Supplementary Table 4 ).
To the best of our knowledge, this is the first observation of ROS1 and ALK fusions in the same individual with NSCLC. We designed the NSCLC CAPP-Seq selector to detect multiple SNVs per tumor. In one patient (P5), this design allowed us to identify a dominant clone with an activating EGFR mutation as well as an erlotinib-resistant subclone with a 'gatekeeper' EGFR T790M mutation 26 . The ratios between clones were identical in a tumor biopsy and in simultaneously sampled plasma (Fig. 4d) , demonstrating that our method has potential for detecting and quantifying clinically relevant subclones.
Patients with stage II or III NSCLC undergoing definitive radiotherapy often have surveillance CT or PET-CT scans that are difficult to interpret owing to radiation-induced inflammatory and fibrotic changes in the lung and surrounding tissues. For patient P13, who was treated with radiotherapy for stage IIB NSCLC, follow-up imaging showed a large mass that was interpreted to represent residual disease. However, ctDNA at the same time point was undetectable ( Fig. 4e) , and the patient remained disease free 22 months later, which supports the ctDNA result. Another patient (P14) was treated with chemoradiotherapy for stage IIIB NSCLC, and follow-up imaging revealed a near-complete response (Fig. 4f) . However, the ctDNA concentration slightly increased following therapy, suggesting progression of occult microscopic disease. Indeed, clinical progression was detected 7 months later, and the patient ultimately succumbed to NSCLC. These data highlight the promise of ctDNA analysis for identifying patients with residual disease after therapy.
We next asked whether the low detection limit of CAPP-Seq would allow monitoring in early-stage NSCLC. Patients P1 (Fig. 4g) and P16 (Fig. 4h ) underwent surgery and stereotactic ablative radiotherapy (SABR) 27 , respectively, for stage IB NSCLC. We detected ctDNA in pretreatment plasma of patient P1 but not at 3 or 32 months following surgery, which suggests that this patient was free of disease and probably cured 28 . For patient P16, the initial surveillance PET-CT scan following SABR showed a residual mass that was interpreted to represent either residual tumor or postradiotherapy inflammation. We detected no evidence of residual disease by ctDNA, supporting the latter hypothesis, and the patient remained free of disease at last follow-up 21 months after therapy. Taken together, these results demonstrate the potential utility of CAPP-Seq for measuring tumor burden in early-and advanced-stage NSCLC and for monitoring ctDNA during distinct types of therapy.
Biopsy-free cancer screening and tumor genotyping Finally, we explored whether CAPP-Seq analysis of ctDNA could potentially be used for cancer screening and biopsy-free tumor genotyping. As proof of principle, we blinded ourselves to the mutations present in each patient's tumor and applied a new statistical method to test for the presence of cancer DNA in each plasma sample in our cohort (Supplementary Fig. 7) . By implementing our cancer screening method for high specificity, we correctly classified 100% of patient plasma samples with ctDNA above fractional abundances of 0.4% with a false-positive rate of 0% ( Fig. 4i and Supplementary  Methods) . CAPP-Seq could therefore potentially improve upon the low positive predictive value of low-dose CT screening in patients at high risk of developing NSCLC 29 .
Separately, when we specifically examined the ability of CAPP-Seq to noninvasively detect actionable mutations in EGFR and KRAS 25 , we correctly identified 100% of mutations at allelic fractions greater than 0.1% with 99% specificity. CAPP-Seq may therefore have utility for biopsy-free tumor genotyping in patients with locally advanced or metastatic NSCLC. However, methodological improvements will be required to detect and genotype stage I tumors without prior knowledge of tumor genotype.
DISCUSSION
In this study, we present CAPP-Seq as a new method for ctDNA quantitation. Its key features include high sensitivity and specificity, lack of a need for patient-specific optimization and coverage of nearly all patients with NSCLC. To our knowledge, CAPP-Seq is the first NGS-based method for ctDNA analysis that achieves both an ultralow detection limit and broad patient coverage at a reasonable cost. Our approach also reduces the potential impact of stochastic noise and biological variability (for example, mutations near the detection limit or subclonal tumor evolution) on tumor burden quantitation by integrating information content across multiple instances and classes of somatic mutations. These features facilitated the detection of minimal residual disease and ctDNA quantitation from stage I NSCLC tumors. Although we focused on NSCLC, our method could be applied to any malignancy for which recurrent mutation data are available.
In many patients, levels of ctDNA are considerably lower than the detection thresholds of previously described sequencing-based methods 13 . For example, pretreatment ctDNA concentration is <0.5% in the majority of patients with lung and colorectal carcinomas 1, 30, 31 . Following therapy, ctDNA concentrations typically drop, thus requiring even lower detection thresholds. Previously published ctDNA detection methods employing amplicon 8, 10, 11 , whole-exome 12 or whole-genome 9,24,32,33 sequencing would not be sensitive enough to detect ctDNA in most patients with NSCLC, even at tenfold or greater sequencing costs ( Fig. 1d and Supplementary Fig. 8) .
To further expand the potential clinical applications of ctDNA quantitation, additional gains in the detection threshold are desirable. Potential approaches include using barcoding strategies that suppress PCR errors resulting from library preparation 34, 35 and increasing the amount of plasma used for ctDNA analysis above the average of ~1.5 ml used in our study. A second limitation of CAPP-Seq is the potential for inefficient capture of fusions, which could lead to underestimates of tumor burden (for example, P9; Supplementary Methods). However, this bias can be analytically addressed when other reporter types are present (for example, P6; Supplementary  Table 4 ). Finally, although we found that CAPP-Seq could quantitate CNAs, our current selector design did not prioritize these types of aberrations. We anticipate that adding coverage for certain CNAs will prove useful for monitoring various types of cancers.
In summary, targeted hybrid capture and high-throughput sequencing of plasma DNA allows for highly sensitive and noninvasive detection of ctDNA in the vast majority of patients with NSCLC at low cost. CAPP-Seq could therefore be routinely applied clinically and has the potential for accelerating the personalized detection, therapy and monitoring of cancer. We anticipate that CAPP-Seq will prove valuable in a variety of clinical settings, including the assessment of cancer DNA in alternative biological fluids and specimens with low cancer cell content. npg METHODS Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Patient selection. Between April 2010 and June 2012, patients undergoing treatment for newly diagnosed or recurrent NSCLC enrolled in a study approved by the Stanford University Institutional Review Board and provided informed consent. Enrolled patients had not received blood transfusions within 3 months of blood collection. Patient characteristics are listed in Supplementary Table 3 . All treatments and radiographic examinations were performed as part of standard clinical care. Volumetric measurements of tumor burden were based on visible tumor on CT and calculated according to the ellipsoid formula: (length/2) × width 2 .
Sample collection and processing. Peripheral blood from patients was collected in EDTA Vacutainer tubes (Becton Dickinson). Blood samples were processed within 3 h of collection. Plasma was separated by centrifugation at 2,500g for 10 min, transferred to microcentrifuge tubes and centrifuged at 16,000g for 10 min to remove cell debris. The cell pellet from the initial spin was used for isolation of germline genomic DNA from PBLs with the DNeasy Blood & Tissue Kit (Qiagen). Matched tumor DNA was isolated from formalin-fixed, paraffin-embedded specimens or from the cell pellet of pleural effusions. Genomic DNA was quantified by Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen).
Cell-free DNA purification and quantification. Circulating DNA was isolated from 1-5 mL plasma with the QIAamp Circulating Nucleic Acid Kit (Qiagen). The concentration of purified plasma DNA was determined by qPCR using an 81-bp amplicon on chromosome 1 (ref. 24 ) and a dilution series of intact male human genomic DNA (Promega) as a standard curve. Power SYBR Green was used for qPCR on a HT7900 Real Time PCR machine (Applied Biosystems), using standard PCR thermal cycling parameters.
Next-generation sequencing library construction. Indexed Illumina NGS libraries were prepared from plasma DNA and shorn tumor, germline and cell line genomic DNA. For patient plasma DNA, 7-32 ng DNA were used for library construction without additional fragmentation. For tumor, germline and cell line genomic DNA, 69-1,000 ng DNA was sheared before library construction with a Covaris S2 instrument using the recommended settings for 200-bp fragments. Details are provided in Supplementary Table 2 .
The NGS libraries were constructed using the KAPA Library Preparation Kit (Kapa Biosystems) employing a DNA polymerase possessing strong 3′→5′ exonuclease (or proofreading) activity and displaying the lowest published error rate (i.e., highest fidelity) of all commercially available B-family DNA polymerases 36, 37 . The manufacturer's protocol was modified to incorporate with-bead enzymatic and cleanup steps using Agencourt AMPure XP beads (Beckman-Coulter) 38 . Ligation was performed for 16 h at 16 °C using 100-fold molar excess of indexed Illumina TruSeq adapters. Single-step size selection was performed by adding 40 µL (0.8×) of PEG buffer to enrich for ligated DNA fragments. The ligated fragments were then amplified using 500 nM Illumina backbone oligonucleotides and 4-9 PCR cycles, depending on input DNA mass. Library purity and concentration was assessed by spectrophotometer (NanoDrop 2000) and qPCR (KAPA Biosystems), respectively. Fragment length was determined on a 2100 Bioanalyzer using the DNA 1000 Kit (Agilent).
Library design for hybrid selection. Hybrid selection was performed with a custom SeqCap EZ Choice Library (Roche NimbleGen). This library was designed through the NimbleDesign portal (v1.2.R1) using genome build hg19 NCBI Build 37.1/GRCh37 and with Maximum Close Matches set to 1. Input genomic regions were selected according to the most frequently mutated genes and exons in NSCLC and were chosen to iteratively maximize the number of mutations per tumor while minimizing selector size. These regions were identified from the COSMIC database, TCGA and other published sources as described in the Supplementary Methods. Final selector coordinates are provided in Supplementary Table 1 .
Hybrid selection and next-generation sequencing. NimbleGen SeqCap EZ Choice was used according to the manufacturer's protocol with modifications.
To assess the significance of tumor burden estimates in plasma DNA using SNVs, we compared patient-specific SNV frequencies to the null distribution of selector-wide background alleles. Indels were analyzed separately using mutation-specific background rates and Z-score statistics. Fusion breakpoints were considered significant when present with >0 read support due to their ultralow false detection rate.
For each patient, we calculated a ctDNA detection index (akin to a falsepositive rate) based on P value integration from his or her array of reporters ( Table 1 and Supplementary Table 4 ). Specifically, for cases where only a single reporter type was present in a patient's tumor, the corresponding P value was used. If SNV and indel reporters were detected and if each independently had a P value <0.1, we combined their respective P values using Fisher's method 43 . Otherwise, given the prioritization of SNVs in the selector design, the SNV P value was used. If a fusion breakpoint identified in a tumor sample (i.e., involving ROS1, ALK or RET) was recovered in plasma DNA from the same patient, it trumped all other mutation types, and its P value (~0) was used. If a fusion detected in the tumor was not found in corresponding plasma (potentially owing to hybridization inefficiency; Supplementary Methods), the P value for any remaining mutation type(s) was used. The ctDNA detection index was considered significant if the metric was ≤0.05 (approximate false-positive rate ≤5%), the threshold that maximized CAPP-Seq sensitivity and specificity in ROC analyses (determined by Euclidean distance to a perfect classifier; i.e., a true-positive rate equal to 1 and a false-positive rate equal to 0; Figs. 3 and 4, Table 1 and Supplementary Table 4 ).
We evaluated CAPP-Seq performance in a blinded fashion by masking all patient identifying information, including disease stage, circulating DNA time point, treatment, etc. We then applied our ctDNA detection index across the entire grid of deidentified plasma DNA samples (13 patient-specific sets of somatic reporters across 40 plasma samples, or 520 pairs). To calculate sensitivity and specificity, we 'unblinded' ourselves and grouped patient samples into cancer-positive (i.e., cancer was present in the patient's body), cancernegative (i.e., patient was cured) or cancer-unknown (i.e., insufficient data to determine true classification) categories (Fig. 3a,b and Supplementary Fig. 6) . ROC analyses and significance estimates were performed using GraphPad Prism 6.
Additional details are presented in the Supplementary Methods.
